Shinpoong Pharm (019170.KS) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

019170.KS · Stock Price

KRW 11,510+4,040 (+54.08%)

Market Cap: $403.4M

Historical price data

Market Cap: $403.4MFounded: 1962Employees: 500-1500HQ: Seoul, South Korea

Sector Ranking#20 in Small Molecule Drugs

Overview

Shinpoong Pharmaceutical has established itself as a critical global supplier of malaria treatments, with a mission to improve public health in underserved regions through effective and affordable anti-infectives. Its core achievement is the development and global commercialization of sophisticated fixed-dose ACTs, including Pyramax®. The company's strategy leverages its deep formulation and regulatory expertise to expand its infectious disease portfolio, pursue geographic growth, and enhance its manufacturing and quality systems, as evidenced by recent ISO certifications and 2026 business initiatives.

Infectious DiseasesMalariaNeglected Tropical Diseases

Technology Platform

Specialized expertise in the formulation, clinical development, and global registration of fixed-dose combination therapies, particularly artemisinin-based combinations (ACTs), optimized for stability in tropical conditions and pediatric use.

Funding History

1

IPOUndisclosedUndisclosedJun 15, 1990

Opportunities

Significant growth potential exists in expanding the label and geographic reach of its flagship antimalarial Pyramax®, as well as in leveraging its global health platform to develop and commercialize treatments for other neglected tropical diseases.

Increased global focus and funding for antimicrobial resistance (AMR) could also open new avenues for its anti-infective R&D.

Risk Factors

The company faces high concentration risk in its malaria portfolio, revenue volatility dependent on unpredictable global health tenders, and operational challenges in emerging markets.

Competition from large generic manufacturers and the constant threat of drug resistance are persistent industry risks.

Competitive Landscape

Shinpoong competes in a concentrated market against large generic and specialty pharma companies like Ipca, Guilin Pharma, Sanofi, and Novartis for WHO-prequalified antimalarials. It differentiates through its specific expertise in pyronaridine-based ACTs, vertical integration, and deep partnerships with global health organizations.